Third Quarter 2025 Financial Results November 5, 2025 Cautionary Note Regarding Forward-Looking Statements Unless otherwise noted, all references in this presentation to net income (loss), net income (loss) per share, adjusted operating income (loss) and adjusted operating income (loss) per share should be read as net income (loss) income (loss) available to Enact's common stockholders per diluted share, respectively. 2 1 U.S. Generally Accepted Accounting Principles Third Quarter Key Takeaways Insurance in ...

Q3 2025 Earnings November 6, 2025 8:00am ET Forward-Looking Statements This presentation, conference call and discussions that follow contain statements concerning our expectations, anticipations and beliefs regarding the future, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertai ...

Unlocking value through digital and Al leadership Lloyds Banking Group 6 November 2025 Introduction Charlie Nunn Welcome and introduction Our strategic seminar series Charlie Nunn Group Chief Executive October 2023: Deepen and innovate in Consumer November 2023: Develop our Corporate & Institutional business March 2024: Broaden our Mass Affluent and IP&I offering June 2024: Digitise and diversify our BCB business November 2025: Unlocking value through digital and Al leadership Today's presenters Ron van Kem ...

Unlocking Long-Term Growth through our Infrastructure, Expertise and Partnerships C o r p o r a t e D e c k | N o v e m b e r 6 , 2 0 2 5 Disclaimer This presentation contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of our future financial and operating performance and growth plans, taking into account the information currently available to us. These statements are not statem ...

Third Quarter 2025 Earnings Supplemental Materials September 2024 November 5, 2025 Solving problems. Improving lives. Advancing medicines. Disclaimer Certain statements in this press release include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. Thes ...

November 6, 2025 3Q 2025 Financial Results Overview DuPont de Nemours, Inc. ("DuPont") completed the previously announced separation of its Electronics business (the "Electronics Separation") into an independent public company, Qnity Electronics, Inc. ("Qnity"), by way of the distribution to DuPont's stockholders of record as of October 22, 2025 of all the issued and outstanding common stock of Qnity on November 1, 2025 (the "Distribution"). As a result, beginning in the fourth quarter of 2025, the financia ...

业绩总结 - BeOne在全球范围内获得了超过40项BRUKINSA®（zanubrutinib）的批准[5] - BeOne在全球范围内获得了超过175项TEVIMBRA®（tislelizumab）的批准[5] - BeOne的临床开发管线包括40多个临床和商业阶段的资产[5] - BeOne在2025年第三季度的财务报告中未提供具体的收入或利润数据[1] 用户数据 - BeOne在全球范围内的临床试验中共招募了超过30,000名患者[5] - BGB-3111-304（SEQUOIA）在TN CLL/SLL人群中计划招募784名患者，已获得批准[30] - BGB-3111-306（MANGROVE）在TN MCL人群中计划招募510名患者，处于维护阶段[30] - BGB-3111-308（MAHOGANY）在R/R MZL和FL人群中计划招募780名患者，目前正在招募中[30] - BGB-3111-212（ROSEWOOD）在R/R FL人群中计划招募217名患者，已获得批准[30] - BGB-3111-305（ALPINE）在R/R CLL人群中计划招募652名患者，已获得批准[30] 新产品和新技术研发 - 自2025年第二季度更新以来，BeOne新增了多个项目进入临床试验阶段，包括BTKi + BCL2i和EGFR x MET x MET ADC等[9] - Sonrotoclax被认为是潜在的最佳BCL2抑制剂，具有差异化的特征[31] - BGB-16673 BTK CDAC被视为潜在的首个BTK降解剂[33] 市场扩张和并购 - BeOne的药物开发依赖于第三方进行药物开发、生产和商业化[3] - BeOne的临床开发管线涵盖了多个治疗领域，包括血液学、实体肿瘤和炎症免疫学[6][7] 负面信息 - BeOne的药物候选者的临床结果可能不支持进一步开发或市场批准[3] 其他新策略和有价值的信息 - BeOne在中国的多个产品均处于不同的临床阶段，包括BRUKINSA®（zanubrutinib）和TEVIMBRA®（tislelizumab），均为全球商业权[51]

Forward-Looking and Cautionary Statements This presentation does not constitute an offering of securities and the information contained herein is subject to the information contained in the continuous disclosure documents of Solaris Resources Inc. ("Solaris" or the "Company"). No securities commission or other regulatory authority in Canada or any other country or jurisdiction has in any way passed on the merits of this presentation and no representation or warranty is made by Solaris to that effect. The in ...

Third Quarter Financial Results NOVEMBER 5, 2025 Mike Thomson Chief Executive Officer & President Deb McCann Chief Financial Officer Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Unisys cautions readers that the assumptions forming the basis for forward-looking state ...

THIRD QUARTER 2025 HIGHLIGHTS 1 SAFE HARBOR STATEMENT Forward Looking Statements This presentation, as well as other written or oral communications made from time to time by us, may contain certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements refer to our current expectations and projections relating to our financial condition, results of operations, plans, objectives, strategies, future performance, and business. All sta ...